valuation model, page-13

the idenix $450M deal with gsk has been compared to what might be for ATC

realistically, that deal is more like what AVX might achieve for the Integrase program

for example here is a recent tibotec preclinical deal for an hcv program for $450M
http://www.genengnews.com/news/bnitem.aspx?name=35600478

ATC will get more upfront and in royalties than these types of deals

oh, and I suspect more are interested in the integrase program if tibotec dont bight...